Matches in SemOpenAlex for { <https://semopenalex.org/work/W2732019947> ?p ?o ?g. }
- W2732019947 endingPage "709" @default.
- W2732019947 startingPage "701" @default.
- W2732019947 abstract "Purpose To explore the prostate-specific membrane antigen (PSMA)–avid distribution of prostate cancer (PC) on positron emission tomography (PET), both at the time of initial diagnosis and at the time of relapse after definitive local treatment. Methods and Materials A total of 179 PSMA PET scans in patients with nil or ≤3 lesions on conventional imaging were retrospectively categorized into 3 subgroups: group A, high-risk PC with no prior definitive therapy (n=34); group B, prior prostatectomy (n=75); and group C, prior radiation therapy (n=70). The numbers and locations of the PSMA-avid lesions were mapped. The PSMA-positive lesions were identified subjectively by a nuclear medicine physician on the basis of clinical experience and taking into account the recent literature and artefacts. Results A total of 893 PSMA-avid lesions were identified; at least 1 lesion was detected in 80% of all scans. A high detection rate was present even at very low serum PSA levels (eg, at PSA ≤0.20 ng/mL in group B, the detection rate was 46%). Thirty-eight percent of studies revealed extrapelvic disease (41%, 31%, and 46% in groups A, B, and C, respectively). Almost one-third of all studies showed only oligometastases (24%, 36%, and 31% in groups A, B, and C, respectively). A large proportion of these (40%) were a solitary lesion. Conclusions Prostate-specific membrane antigen PET demonstrated a large number of otherwise unknown metastatic lesions. Therefore we recommend PSMA PET for more accurate assessment of disease burden in initial staging of high-risk PC, as well as for restaging in patients with prostate-specific antigen relapse after primary therapies. Furthermore, a high proportion of oligometastases on PSMA PET provides a prime opportunity to investigate the role of targeted local therapies for oligometastatic PCs. To explore the prostate-specific membrane antigen (PSMA)–avid distribution of prostate cancer (PC) on positron emission tomography (PET), both at the time of initial diagnosis and at the time of relapse after definitive local treatment. A total of 179 PSMA PET scans in patients with nil or ≤3 lesions on conventional imaging were retrospectively categorized into 3 subgroups: group A, high-risk PC with no prior definitive therapy (n=34); group B, prior prostatectomy (n=75); and group C, prior radiation therapy (n=70). The numbers and locations of the PSMA-avid lesions were mapped. The PSMA-positive lesions were identified subjectively by a nuclear medicine physician on the basis of clinical experience and taking into account the recent literature and artefacts. A total of 893 PSMA-avid lesions were identified; at least 1 lesion was detected in 80% of all scans. A high detection rate was present even at very low serum PSA levels (eg, at PSA ≤0.20 ng/mL in group B, the detection rate was 46%). Thirty-eight percent of studies revealed extrapelvic disease (41%, 31%, and 46% in groups A, B, and C, respectively). Almost one-third of all studies showed only oligometastases (24%, 36%, and 31% in groups A, B, and C, respectively). A large proportion of these (40%) were a solitary lesion. Prostate-specific membrane antigen PET demonstrated a large number of otherwise unknown metastatic lesions. Therefore we recommend PSMA PET for more accurate assessment of disease burden in initial staging of high-risk PC, as well as for restaging in patients with prostate-specific antigen relapse after primary therapies. Furthermore, a high proportion of oligometastases on PSMA PET provides a prime opportunity to investigate the role of targeted local therapies for oligometastatic PCs." @default.
- W2732019947 created "2017-07-14" @default.
- W2732019947 creator A5010010965 @default.
- W2732019947 creator A5015082473 @default.
- W2732019947 creator A5021111124 @default.
- W2732019947 creator A5021943155 @default.
- W2732019947 creator A5031495990 @default.
- W2732019947 creator A5037579052 @default.
- W2732019947 creator A5050101777 @default.
- W2732019947 creator A5068472422 @default.
- W2732019947 creator A5068687486 @default.
- W2732019947 creator A5083174455 @default.
- W2732019947 date "2017-11-01" @default.
- W2732019947 modified "2023-10-16" @default.
- W2732019947 title "Prostate-Specific Membrane Antigen Positron Emission Tomography–Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning" @default.
- W2732019947 cites W1490266165 @default.
- W2732019947 cites W1541574466 @default.
- W2732019947 cites W1970232130 @default.
- W2732019947 cites W1973942000 @default.
- W2732019947 cites W1987809679 @default.
- W2732019947 cites W1989171469 @default.
- W2732019947 cites W2011197894 @default.
- W2732019947 cites W2014999922 @default.
- W2732019947 cites W2027042157 @default.
- W2732019947 cites W2032856096 @default.
- W2732019947 cites W2051871489 @default.
- W2732019947 cites W2070262092 @default.
- W2732019947 cites W2080006760 @default.
- W2732019947 cites W2091083791 @default.
- W2732019947 cites W2111784792 @default.
- W2732019947 cites W2115092415 @default.
- W2732019947 cites W2118742901 @default.
- W2732019947 cites W2123719078 @default.
- W2732019947 cites W2127240958 @default.
- W2732019947 cites W2127407300 @default.
- W2732019947 cites W2128021809 @default.
- W2732019947 cites W2134548622 @default.
- W2732019947 cites W2137670219 @default.
- W2732019947 cites W2148867458 @default.
- W2732019947 cites W2156235972 @default.
- W2732019947 cites W2179945673 @default.
- W2732019947 cites W2234163738 @default.
- W2732019947 cites W2274991296 @default.
- W2732019947 cites W2299477037 @default.
- W2732019947 cites W2324060427 @default.
- W2732019947 cites W2410896679 @default.
- W2732019947 cites W2416073795 @default.
- W2732019947 cites W2470255787 @default.
- W2732019947 cites W2487033212 @default.
- W2732019947 cites W2511755939 @default.
- W2732019947 cites W2521395094 @default.
- W2732019947 cites W2525349940 @default.
- W2732019947 cites W2620145152 @default.
- W2732019947 cites W4236841223 @default.
- W2732019947 doi "https://doi.org/10.1016/j.ijrobp.2017.06.2448" @default.
- W2732019947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29280465" @default.
- W2732019947 hasPublicationYear "2017" @default.
- W2732019947 type Work @default.
- W2732019947 sameAs 2732019947 @default.
- W2732019947 citedByCount "47" @default.
- W2732019947 countsByYear W27320199472018 @default.
- W2732019947 countsByYear W27320199472019 @default.
- W2732019947 countsByYear W27320199472020 @default.
- W2732019947 countsByYear W27320199472021 @default.
- W2732019947 countsByYear W27320199472022 @default.
- W2732019947 countsByYear W27320199472023 @default.
- W2732019947 crossrefType "journal-article" @default.
- W2732019947 hasAuthorship W2732019947A5010010965 @default.
- W2732019947 hasAuthorship W2732019947A5015082473 @default.
- W2732019947 hasAuthorship W2732019947A5021111124 @default.
- W2732019947 hasAuthorship W2732019947A5021943155 @default.
- W2732019947 hasAuthorship W2732019947A5031495990 @default.
- W2732019947 hasAuthorship W2732019947A5037579052 @default.
- W2732019947 hasAuthorship W2732019947A5050101777 @default.
- W2732019947 hasAuthorship W2732019947A5068472422 @default.
- W2732019947 hasAuthorship W2732019947A5068687486 @default.
- W2732019947 hasAuthorship W2732019947A5083174455 @default.
- W2732019947 hasConcept C121608353 @default.
- W2732019947 hasConcept C126322002 @default.
- W2732019947 hasConcept C126838900 @default.
- W2732019947 hasConcept C142724271 @default.
- W2732019947 hasConcept C143998085 @default.
- W2732019947 hasConcept C201645570 @default.
- W2732019947 hasConcept C20417620 @default.
- W2732019947 hasConcept C2775842073 @default.
- W2732019947 hasConcept C2776235491 @default.
- W2732019947 hasConcept C2779466945 @default.
- W2732019947 hasConcept C2780192828 @default.
- W2732019947 hasConcept C2781156865 @default.
- W2732019947 hasConcept C2781406297 @default.
- W2732019947 hasConcept C2989005 @default.
- W2732019947 hasConcept C509974204 @default.
- W2732019947 hasConcept C71924100 @default.
- W2732019947 hasConceptScore W2732019947C121608353 @default.
- W2732019947 hasConceptScore W2732019947C126322002 @default.
- W2732019947 hasConceptScore W2732019947C126838900 @default.
- W2732019947 hasConceptScore W2732019947C142724271 @default.
- W2732019947 hasConceptScore W2732019947C143998085 @default.